Harmony Biosciences (NASDAQ:HRMY) Issues Earnings Results

Harmony Biosciences (NASDAQ:HRMY) released its quarterly earnings data on Tuesday. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19, Zacks reports. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. During the same quarter in the previous year, the company earned $0.67 EPS. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. Harmony Biosciences updated its FY 2025 guidance to EPS.

Harmony Biosciences Trading Up 6.4 %

HRMY stock traded up $1.91 during mid-day trading on Tuesday, reaching $31.87. 350,170 shares of the stock traded hands, compared to its average volume of 575,252. The business has a 50-day moving average price of $31.34 and a two-hundred day moving average price of $34.04. The stock has a market capitalization of $1.83 billion, a PE ratio of 15.02, a PEG ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences has a one year low of $26.47 and a one year high of $41.61.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on HRMY shares. Mizuho boosted their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 18th. Needham & Company LLC reissued a “buy” rating and set a $49.00 price target on shares of Harmony Biosciences in a research note on Tuesday. UBS Group reduced their price objective on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, April 28th. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price for the company. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $52.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.